Toujeo Solo Star

GPTKB entity

Statements (51)
Predicate Object
gptkbp:instance_of gptkb:diabetes
gptkbp:brand gptkb:Toujeo
gptkbp:clinical_trial approved for use
gptkbp:clinical_use type 2 diabetes
type 1 diabetes
gptkbp:contraindication hypersensitivity to insulin glargine
severe hypoglycemia
gptkbp:country_of_origin gptkb:France
gptkbp:dosage_form 300 units/m L
gptkbp:effective_date gptkb:2015
gptkbp:form injectable solution
Solo Star pen
https://www.w3.org/2000/01/rdf-schema#label Toujeo Solo Star
gptkbp:indication once-daily basal insulin therapy
gptkbp:ingredients gptkb:insulin_glargine
gptkbp:manufacturer gptkb:Sanofi
gptkbp:mechanism_of_action long-acting insulin
gptkbp:packaging pre-filled pen
gptkbp:patient_education diet and exercise recommendations
recognizing hypoglycemia symptoms
importance of blood glucose monitoring
how to store the pen
how to use the pen
gptkbp:patient_population adults and children 6 years and older
gptkbp:pharmaceutical_formulation clear solution
gptkbp:pharmacokinetics provides a steady release of insulin
steady-state concentration achieved after 2-4 days
gptkbp:provides_guidance_on recommended for basal insulin therapy
adjustment based on blood glucose levels
used in combination with mealtime insulin
gptkbp:regulatory_compliance FDA approved
EMA approved
gptkbp:related_products gptkb:Basaglar
gptkb:Lantus
gptkbp:route_of_administration subcutaneous injection
gptkbp:safety keep out of reach of children
monitor for allergic reactions
consult healthcare provider for dosage adjustments
dispose of used pens properly
do not share pens between patients
gptkbp:service_frequency once daily
gptkbp:shelf_life 28 days after opening
gptkbp:side_effect weight gain
injection site reactions
hypoglycemia
gptkbp:storage refrigerated
gptkbp:used_for diabetes management
gptkbp:website rotate injection sites
subcutaneous injection in the abdomen
gptkbp:bfsParent gptkb:Toujeo
gptkbp:bfsLayer 6